Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > TXG 10x Genomics > Key Indicators
TXG 10x Genomics
35.840
-0.600-1.65%
Post Mkt Price
35.8400.0000.00%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
3.56% 174.2821 46.78% 198.6456 58.54% 217.9386 58.54% 217.9386
Receivable Turnover(T)
-25.57% 7.3288 -1.15% 7.4539 1.73% 7.1887 1.73% 7.1887
Inventory Turnover(T)
9.31% 1.8355 -22.69% 1.6146 -36.26% 1.6478 -36.26% 1.6478
Fixed Assets Turnover(T)
-28.49% 2.106 -9.17% 2.3242 -20.97% 2.8009 -20.97% 2.8009
Total Asset Rate(T)
-3.24% 0.5032 19.90% 0.5101 29.34% 0.5035 29.34% 0.5035
ROIC
78.62% -16.483% 87.51% -10.279% 92.17% -6.787% 92.17% -6.787%
ROE
78.80% -18.174% 87.55% -11.427% 92.01% -7.481% 92.01% -7.481%
ROA
77.71% -14.399% 86.64% -9.103% 91.55% -5.977% 91.55% -5.977%
Efficiency Ratios
ROA 5 Year Average
-- -- -- -- -- -44.517% -- --
Profitability Ratios TTM
Gross Margin
-8.71% 78.853% 1.99% 83.471% 5.54% 84.895% 5.54% 84.895%
Operating Margin
-132.54% -27.426% 25.55% -16.953% 62.22% -10.788% 62.22% -10.788%
Net Margin
76.97% -28.617% 88.86% -17.847% 93.46% -11.870% 93.46% -11.870%
EBITDA Margin
81.54% -0.2138% 92.86% -0.1077% 97.08% -0.0501% 97.08% -0.0501%
R & D Expense Ratio
23.96% 50.450% 12.00% 46.870% 4.58% 43.170% 4.58% 43.170%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Financial Health Ratios
Long-Term Debt to Equity Ratio
38.30% 11.619% 31.51% 11.595% 21.79% 9.400% 21.79% 9.400%
Total Assets to Common Equity
2.60% 127.833% -1.91% 124.367% -0.90% 124.617% -0.90% 124.617%
Debt to Asset Ratio
40.00% 12.638% 30.17% 12.542% 17.67% 10.027% 17.67% 10.027%
Current Ratio
-15.58% 5.6504 19.36% 7.3834 3.34% 6.7743 3.34% 6.7743
Quick Ratio
-18.93% 4.8846 16.52% 6.5206 0.73% 6.0957 0.73% 6.0957
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- -19.11% 49.663% -- --
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.
CEO: Dr. Serge Saxonov, PhD
Market: NASDAQ
Listing Date: 09/12/2019
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist